In a phase III trial comparing ABVD and Stanford V chemotherapy in advanced-stage cHL, increased expression of CD68 and CD163 represented an independent predictor of worse failure-free survival and OS (24). This evidence concerns the gene CD163 and classic Hodgkin lymphoma.